Industry forecasting firm Visiongain released its Antibacterial Drugs Market Report 2024-2034 today, which projected the antibacterial drug market to grow at a compound annual growth rate of 3.6 percent during the 10-year forecast period.
One reason cited for this growth is the impact of artificial intelligence and machine learning on the drug discovery process. The report highlights the recent discovery of a drug to treat the bacteria Acinetobacter baumannii, which built upon efforts two C3.ai Co-P.I.s who worked on the breakthrough, MIT professors Regina Barzilay and Tommi Jaakkola, had make to investigate interventions for COVID-19 that were funded by the C3.ai Digital Transformation Institute.
The new drug was identified from a library of ~7,000 potential drug compounds using a machine-learning model trained to evaluate whether a chemical compound will inhibit the growth of A. baumannii. Once approved, the drug could help combat Acinetobacter baumannii found in hospitals that leads to pneumonia, meningitis, and other serious infections.
See the Visiongain report summary here.
See our news brief on the drug discovery study here.